Introduction: Little is known about market access to biosimilars from a health economic
perspective, except for studies that compute the budget impact of biosimilar use. Areas …

Lower-income countries (‎ LICs)‎ in the WHO European Region generally have poorer health
status and more limited resources than higher-income countries. This creates pressing …

Background Biosimilars constitute a pathway for sustainable financing of healthcare systems
in the era of expensive biologics. However, such a pathway is not free of challenges. Since …

Background: The aim of this study was to investigate the impact of selected legislative
initiatives and their implementation for off-patent medicinal products in Slovakia compared …

Background. Diabetes mellitus rates and associated costs continue to rise across Europe
enhancing health authority focus on its management. The risk of complications is enhanced …

Introduction: There is significant difference in utilization of patented medicines in the EU, as
pharmaceuticals at Western European price levels are usually not cost-effective in Central …

To date, numerous biosimilars are available in Europe and the practice of switching
between originator and biosimilar or between two different biosimilars has become very …

Introduction While biosimilar medicines can contribute to the sustainability of healthcare
systems, their utilization rate varies across European countries. This study aims to identify …

Background. On September 5, 2019, British Columbia announced a new policy (the
Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with …

Objectives The current study is aimed at proposing a standardized regulatory model for
biosimilar development and approval for adoption by BRICS-TM agencies, based on …